- Home
- PEPG vs ALLK Comparison
PEPG vs ALLK Comparison
Compare PEPG & ALLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PEPG
- ALLK
- Stock Information
- Founded
- PEPG 2018
- ALLK 2012
- Country
- PEPG United States
- ALLK United States
- Employees
- PEPG 76
- ALLK N/A
- Industry
- PEPG Biotechnology: Pharmaceutical Preparations
- ALLK Biotechnology: Pharmaceutical Preparations
- Sector
- PEPG Health Care
- ALLK Health Care
- Exchange
- PEPG Nasdaq
- ALLK Nasdaq
- Market Cap
- PEPG 118.3M
- ALLK 101.0M
- IPO Year
- PEPG 2022
- ALLK 2018
- Fundamental
- Price
- PEPG $3.63
- ALLK $1.20
- Analyst Decision
- PEPG Buy
- ALLK Hold
- Analyst Count
- PEPG 3
- ALLK 5
- Target Price
- PEPG $14.67
- ALLK $1.67
- AVG Volume (30 Days)
- PEPG 297.7K
- ALLK 334.5K
- Earning Date
- PEPG 11-07-2024
- ALLK 11-06-2024
- Dividend Yield
- PEPG N/A
- ALLK N/A
- EPS Growth
- PEPG N/A
- ALLK N/A
- EPS
- PEPG N/A
- ALLK N/A
- Revenue
- PEPG N/A
- ALLK N/A
- Revenue This Year
- PEPG N/A
- ALLK N/A
- Revenue Next Year
- PEPG N/A
- ALLK N/A
- P/E Ratio
- PEPG N/A
- ALLK N/A
- Revenue Growth
- PEPG N/A
- ALLK N/A
- 52 Week Low
- PEPG $2.90
- ALLK $0.54
- 52 Week High
- PEPG $19.30
- ALLK $3.36
- Technical
- Relative Strength Index (RSI)
- PEPG 27.87
- ALLK 57.22
- Support Level
- PEPG $4.00
- ALLK $1.00
- Resistance Level
- PEPG $5.72
- ALLK $1.10
- Average True Range (ATR)
- PEPG 0.68
- ALLK 0.10
- MACD
- PEPG -0.09
- ALLK 0.02
- Stochastic Oscillator
- PEPG 18.48
- ALLK 52.63
About PEPG PepGen Inc.
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle and the central nervous system. Its pipeline products are; PGN-EDO51, PGN-EDODM1, and others including PGN-EDO53 and PGN-EDO45.
About ALLK Allakos Inc.
Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. The company's lead program, AK006 targets Siglec-6, an inhibitory receptor expressed selectively on mast cells. Binding of AK006 to Siglec-6 is designed to activate the native inhibitory function of the receptor which in turn reduces mast cell activation.